In this phase I trial, the combination of the PKC and AKT pathway inhibitor enzastaurin with bevacizumab (Avastin) did not appear to alter the pharmacokinetics or toxicity profiles of either drug. Antitumor activity was particularly promising in ovarian cancer and when enzastaurin was given twice daily. In ovarian cancer patients, the response rate was 32.3%, with 4 complete responses, 6 partial responses, and 14 pts with stable disease. The median time to disease progression or death in ovarian cancer was 8.3 months, longer than the researchers would have anticipated with bevacizumab monotherapy. - Libby's H*O*P*E*